Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417894 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2183805 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16342359 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2037115 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16323109 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL557403 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL25176741 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2182221 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL20897215 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL28595399 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | claimed |
| CN-119751308-A | Method for preparing telipopeptide side chain intermediate | 攀枝花学院 | 2025-04-04 | — | — | CN | claimed |
| CN-119661685-A | Canagliflozin peptide synthesis method | 杭州思诺达医药科技有限责任公司 | 2025-03-21 | — | — | CN | claimed |
| WO-2025052429-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TIRZEPATIDE | NEULAND LABORATORIES LIMITED (IN) | 2025-03-13 | — | — | WO | claimed |
| CN-119161446-B | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119161446-A | Process for preparing amylin analogues | 杭州诺泰诺和生物医药科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| WO-2024134676-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE | DR. REDDY’S LABORATORIES LIMITED (IN) | 2024-06-27 | — | — | WO | claimed |
| CN-117986347-A | Synthesis method of canagliptin | 杭州思诺达医药科技有限责任公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117858864-A | Compounds and methods for liquid phase synthesis | 伊莱利利公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117106055-A | Synthesis method of telipopeptide | 杭州思诺达医药科技有限责任公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2026108124-A1 | METHOD FOR PREPARING AMYLIN ANALOG | 杭州诺泰诺和生物医药科技有限公司 (CN) | 2026-05-28 | — | — | WO | disclosed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4745153-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2008087189-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2005082404-A2 | GLP-2 DERIVATIVES MODIFIED BY LIPOPHILIC SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2005-09-09 | — | — | WO | disclosed |
| EP-1554308-A2 | GLUCAGON-LIKE PEPTIDE - 2 VARIANTS | NOVO NORDISK A/S (DK) | 2005-07-20 | — | — | EP | disclosed |
| US-20040122210-A1 | GLP-2 compounds, formulations, and uses thereof | NOVO NORDISK A/S (DK) | 2004-06-24 | — | — | US | disclosed |
| WO-2004035624-A2 | GLUCAGON - LIKE PEPTIDE - 2 VARIANTS | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | TSHR 41/4885LMNA 2345/4885NFKB1 4024/4885 |
| US-20250188019-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS | AQP1, CCNB1, CDK2 | TSHR 4528/4885LMNA 186/4885NFKB1 1051/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | TSHR 3291/4885LMNA 70/4885NFKB1 3535/4885 |
| US-20040122210-A1 | GLP-2 compounds, formulations, and uses thereof | GLP1R, GIPR, IAPP | TSHR 254/4885LMNA 1526/4885NFKB1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.